Iovance Biotherapeutics delivered its second consecutive record quarter. It lost $0.05 per share against a consensus estimate of -$0.09, a 44.4% earnings surprise. Revenue of $121.47 million topped the $117.67 million consensus by 3.2% and grew 80.1% year over year, while earnings improved 80.0%. The net loss narrowed to $22.3 million from $91.3 million a year earlier, and the operating loss shrank to about $24 million from nearly $95 million. Those are genuinely strong numbers for a cell-therapy company still building its commercial base. The central tension is that management reaffirmed, rather than raised, its $410-$420 million full-year revenue guidance. With $292 million booked through September, that range implies fourth-quarter revenue of roughly $118-$128 million, flat to modestly up at best after a 22% sequential jump in the third quarter.
The quality of the top-line beat deserves scrutiny. Total revenue rose about $23 million sequentially, but roughly half of that came from Proleukin. Proleukin climbed to about $20 million from about $9 million in the second quarter, and the call acknowledged that part of the jump reflected wholesaler ordering realignment rather than underlying demand. U.S. Amtagvi revenue of about $102 million crossed the $100 million mark and was up roughly 77% year over year. However, sequential Amtagvi growth slowed to about 12% from about 51% in the second quarter. Per-share comparisons also benefit from a weighted share count that rose to roughly 456 million from 364 million a year ago. The narrowing in absolute dollar losses is the more meaningful measure of progress.
Where the quarter was unambiguously better was cost structure. Gross margin, which excludes depreciation and amortization, reached about 60%, up from 56% in the second quarter, 41% in the first quarter and 50% in the fourth quarter of 2025. Management attributed the gain to volume and production cost programs and said it expects further improvement, excluding one-time items. R&D expense fell to about $49 million from $59 million, the fifth straight sequential decline, while SG&A held near $39 million. Cash rose to roughly $382 million from $304 million at the end of June, and the runway was extended again to well into 2029. That runway stood at 3Q27 just three quarters ago. The cash increase despite continued losses suggests the balance sheet has not been funded by operations alone. Management also offered no breakeven timeline.
The pipeline story shifted toward precision TIL. In non-squamous lung cancer, the IOV-LUN-202 trial showed a 24.6% objective response rate (ORR) in 69 patients, slightly below the 26% cited at the end of fiscal 2025. Management is targeting an sBLA in 2027. That framing is a softer milestone than the 2H27 launch referenced on the first-quarter call, and the call's commentary on filing timing was muddled. The more interesting development is a biomarker-selected subgroup with a 59.1% ORR. It has spawned POSITILITY, an 80-patient registrational-intent cohort enrolling now, plus a frontline trial in 2027. Management sizes that biomarker-selected opportunity at about ten times advanced melanoma. Sarcoma confirmed ORR improved to 55.6% (5 of 9 patients) with FDA alignment on an accelerated-approval design. Frontline melanoma data showed a 62.5% ORR, and UK and Swiss approvals are expected by 1Q27. A new chief medical officer arrived, but the interim CEO structure persists.
The market setup is more complicated than the surprise implies. Shares opened at $5.95 after the August report and closed at $8.70 ahead of this release, up 46.2% and about 47% above the $5.91 200-day moving average. That gain masks a round trip. The stock spiked to a 52-week high of $15.37 on October 21, after the early-October guidance raise, and entered the report about 43% below that peak. Investor sentiment improved from 0.047 to 0.155, a meaningful but not euphoric move into modestly positive territory. Most Earnings Whispers trend readings are positive, but AVWAP remains negative, consistent with a stock that has given back much of its October surge.
The bottom line is that Iovance's operating trajectory is clearly improving. Revenue, gross margin, cost discipline and runway all moved in the right direction, and the biomarker strategy adds a credible new leg to the lung opportunity. Bears still have legitimate ammunition. Sequential Amtagvi growth is decelerating, part of the revenue beat came from Proleukin stocking dynamics, and the reaffirmed guide points to a pause in the fourth quarter. Lung timelines have also drifted. Investors now need evidence that Amtagvi demand can re-accelerate into 2027 and that the precision-TIL data hold up in registrational settings.